Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in .
Oxurion NVApril 12, 2021 GMT
Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB), was presented at the annual meeting of the American Association for Cancer Research (AACR).
The data was presented by Dr. Giselle Sholler, Director, Isabella Santos Foundation Solid and Rare Tumor Program, Chair at Beat Childhood Cancer Research Consortium, and Professor, Paediatric Oncology at the Levine Children’s Hospital in Charlotte, NC.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer .
Oxurion NVApril 9, 2021 GMT
Oral presentation of Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB)
Poster presentation of research findings of best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor immune responses
Leuven, Belgium 9th April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that it will make two presentations at the upcoming AACR Virtual Annual Meeting 2021 which will take place from 9 to 14 April.
ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.